CRSP — Crispr Therapeutics AG Share News
0.000.00%
Last trade - 00:00- $4.98bn
- $3.20bn
- $3.51m
Gene therapy makers slide on reports that FDA official Peter Marks resigns
Gene therapy makers slide on reports that FDA official Peter Marks resigns
Focus: Gene therapy loses luster as investors eye quicker returns from weight-loss drugs
Swiss stocks - Factors to watch on February 12
Vertex falls after Q4 profit, sales of gene therapy disappoint
UK Stocks-Factors to watch on Jan 31
UK health system to offer cutting-edge gene therapy for sickle cell disease
Brief: Crispr Therapeutics Highlights Strategic Priorities And Anticipated 2025 Milestones
Editas to reduce about 65% of its workforce over the next six months (updated)
Beam Therapeutics falls after patient death in early trial
Swiss stocks - Factors to watch on November 4
Insight: Why gene therapy for sickle cell is slow to catch on with patients
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say (updated)
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Press Digest: Financial Times - Aug 8
UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder (updated)
UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder
Leerink views Lilly and Sarepta as defensive stocks in turbulent market
U.S. RESEARCH ROUNDUP- Actinium Pharmaceuticals, Albemarle, ArcBest